Tumour markers: from carcinoembryonic antigen to products of hybridoma technology.
Measurements of carcinoembryonic antigen (CEA) concentrations in serum provide a system for monitoring patients with colorectal cancer. The serum tumour marker, CA19-9, recognized by a monoclonal antibody, appears to be the only new marker to add usefully to information from CEA. Their value is in assessing response to therapy and in detecting early surgically resectable relapses. These and other antigens may also be used as targets for imaging with radiolabelled antibodies, assisting in selection for second look surgery. Clinical trials of antibody targeted therapy have begun but convincing benefit remains to be shown.